Real world use of T3 to alleviate symptoms of hypothyroidism during preparation of radioactive iodine ablation: experts viewpoint

P. R. K. Bhargav; Ranadheer Manthri

doi:10.18203/2320-6012.ijrms20244170

Authors

P. R. K. Bhargav Department of Endocrine and Metabolic Surgery, Endocare Hospital, Vijayawada, Andra Pradesh, India
Ranadheer Manthri Department of Nuclear Medicine, MNJ Institute of Oncology Regional Cancer Center, Hyderabad, Telangana, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20244170

Keywords:

Thyroid hormone withdrawal, Liothyronine, Levothyroxine, Hypothyroidism, Differentiated thyroid cancer, Radioactive iodine ablation

Abstract

Thyroid carcinoma is a common endocrine malignancy with most of the cases being diagnosed as differentiated thyroid cancer. Thyroidectomy is the cornerstone of treatment for thyroid carcinoma. Adjuvant therapy with radioactive iodine after surgical resection of all known primary tumor tissue and metastatic foci is advocated. The preparation for radioactive iodine ablation requires elevation of thyroid stimulating hormone to 30 mIU/l for ensuring uptake of I-131 by thyroid follicular cells. In the Indian setting, there are specific challenges in preparation for radioactive iodine ablation including the high cost of recombinant TSH injection which may preclude its use in most patients. The practical approach adopted by Indian endocrinologists, endocrine surgeons and nuclear medicine physicians in the preparation of post-thyroidectomy thyroid cancer patients for radioactive iodine ablation in the real-world setting needs to elaborated and chronicled for providing guidance specific for the constraints encountered in the Indian scenario. Thyroid hormone withdrawal is affected by cessation of levothyroxine for 4 weeks prior to radioactive iodine ablation leading to profound hypothyroidism. This can be addressed by appropriate use of liothyronine (LT3) to substitute levothyroxine after its withdrawal. LT3 administration of 20 mcg twice or thrice a day (40 to 60 mcg/day in divided doses) is the best practice during THW. The duration of LT3 replacement following cessation of levothyroxine, is for 2-3 weeks and then 10-14 days off LT3. These practices are corroborated by evidence from literature and recommendations from guidelines elucidating the use of liothyronine during the period of thyroid hormone withdrawal.

Metrics

Metrics Loading ...

References

Nguyen QT. Diagnosis and treatment of patients with thyroid cancer. Am Health Drug Benefits. 2015;8(1):30-40.

Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid. 2011;21:125–34.

Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, et al. Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. European Journal of Cancer 2017;77:140–52.

Pacini F. 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? Eur Thyroid J. 2022;11(1):210046.

Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S & Goldstein DP. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metabol Clin of North America. 2008;37:457–80.

Liu J, Liu R, Shen X, Zhu G, Li B, Xing M. The genetic duet of BRAF V600E and tert promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer. J Nuclear Med. 2020;61:177–82.

Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E &Pacini F. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metabol. 2010;95:230–7.

Pluijmen MJHM, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AMP, Diamant M, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clinical Endocrinol. 2003;58:428-35.

Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, et al. Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and Thyrogen. Eur J Nuclear Med Mol Imag. 2008;35:1457–63.

Frigo A, Dardano A, Danese E, Davì MV, Moghetti P, Colato C, et al. Chromosometranslocation frequency after radioiodine thyroid remnant ablation: a comparison between recombinant human thyrotropin stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metabol. 2009;94:3472–6.

Edmonds CJ, Hayes S, Kermode JC & Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. British J Radiol. 1977;50:799–807.

Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at the time of I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. European J Nuc Med Molec Imag. 2016;43:224–31.

Marturano I, Russo M, Spadaro A, Latina A, Malandrino P, Regalbuto C. Comparison of conventional L-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing. J Endocrinol Invest. 2015;38:1017-22.

Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nuclear Med. 2008;49:764–70.

Gluvic Z, Obradovic M, Stewart AJ, Essack M, Pitt SJ, Samardzic V, et al. Levothyroxine treatment and the risk of cardiac arrhythmias - focus on the patient submitted to thyroid surgery. Front Endocrinol (Lausanne). 2021;12:758043.

Van Tassell B, Wohlford GF, Linderman JD, Smith S, Yavuz S, Pucino F, et al. Pharmacokinetics of L-triiodothyronine in patients undergoing thyroid hormone therapy withdrawal. Thyroid. 2019;29(10):1371-9.

Bjerkreim BA, Hammerstad SS, Gulseth HL, Berg TJ, Omdal LJ, Lee-Ødegård S, et al. Effect of liothyronine treatment on quality of life in female hypothyroid patients with residual symptoms on levothyroxine therapy: a randomized crossover study. Front Endocrinol (Lausanne). 2022;13:816566.

Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, Luster M, et al. ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer. Eur Thyroid J. 2022;11(1):210046.

Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1-133.